Skip to main content

Advertisement

Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

Fig. 4

Overall major adverse-cardiovascular-events free rates for ACEi and ARB users after propensity score weighting. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, MACE major adverse cardiovascular events

Back to article page